Sign Up Today and Learn More About Excision BioTherapeutics Stock
Invest in or calculate the value of your shares in Excision BioTherapeutics or other pre-IPO companies through EquityZen's platform.
Excision BioTherapeutics Stock (EXCB)
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
About Excision BioTherapeutics Stock
Founded
2015
Headquarters
Philadelphia, PA, US
Industries
Software, Artificial Intelligence, Financial Services
Excision BioTherapeutics Press Mentions
Stay in the know about the latest news on Excision BioTherapeutics
Excision BioTherapeutics Announces Publication Highlighting EBT-107 for the Treatment of Chronic Hepatitis B in bioRxiv
globenewswire • May 17, 2025
Excision BioTherapeutics Presents Data from HBV and HSV Programs at the ASGCT 2025 Annual Meeting
biospace • May 17, 2025
HIV innovation: Six companies developing new treatments in 2025
labiotech • Apr 16, 2025
Excision BioTherapeutics Announces Oral Presentation at the 5th Genome Editing Therapeutics Summit
biospace • Dec 04, 2024
HSV-1 Keratitis Competitive Landscape Market Report 2024 Featuring Key Players - AiCuris Anti-infective Cures, Shanghai BDgene, and Excision BioTherapeutics
globenewswire • Nov 21, 2024
Excision BioTherapeutics Management
Leadership team at Excision BioTherapeutics
Board Member
Vasudev Bailey
Board Member
Ashok Krishnamurthi
Join now and verify your accreditation status to gain access to:
- Excision BioTherapeutics Current Valuation
- Excision BioTherapeutics Stock Price
- Excision BioTherapeutics Management
- Available deals in Excision BioTherapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Excision BioTherapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Excision BioTherapeutics Revenue and Financials
- Excision BioTherapeutics Highlights
- Excision BioTherapeutics Business Model
- Excision BioTherapeutics Risk Factors
- Excision BioTherapeutics Research Report from SACRA Research
Trading Excision BioTherapeutics Stock
How to invest in Excision BioTherapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Excision BioTherapeutics through EquityZen funds. These investments are made available by existing Excision BioTherapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Excision BioTherapeutics stock?
Shareholders can sell their Excision BioTherapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 370K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
